Treatment
There is no known cure for MdDS, as with most balance and gait disorders, some form of displacement exercise is thought helpful (for example walking, jogging, or bicycling but not on a treadmill or stationary bicycle). This has not been well-studied in MdDS. Medications that suppress the nerves and brain circuits involved in balance (for example, the benzodiazepine clonazepam) have been noted to help and can lower symptoms; however, it is not a cure. It is not known whether a medication that suppresses symptoms prolongs symptom duration or not. Vestibular therapy has not proved to be effective in treating MdDS.Additional research is being undertaken into the neurological nature of this syndrome through imaging studies. Many sufferers of this syndrome have found relief by taking histamine blockers or antihistamines (Benadryl for instance). A single Benadryl gel tab at the beginning of the flight and at each 4-hour interval for longer flight. Epidemiology
The condition is thought to be under-reported in the medical literature. A study of 27 cases conducted by Timothy C Hain in 1999 noted all but one patient to be female. The average age in this series was 49 years. This apparent gender disparity, however, may be due in part to the fact that the questionnaire which formed the basis of the study was circulated in a publication with a predominantly female reader base.Subsequent studies have produced conflicting results with regard to the gender distribution of MdDS.
Low-frequency rTMS (e1 Hz) induces local inhibition, whereas high frequency rTMS (Q5 Hz) induces local excitation. The TMS studies have proved to help in lowering the symptoms of MdDS if the treatment is ongoing; however, it is not a cure. Vestibulo-Ocular Reflex Research 2014
At least one clinical trial on readaptation of the vestibulo-ocular reflex undertaken by Dr Mingjia Dai from Mount Sinai Hospital in New York City produced results for a significant percentage of patients who participated in the program.Dr Dai developed an intervention that provided improvement in symptoms for 70% of the patients in the clinical trial phase. The protocol involved a physical manipulation of the patient intended to readapt the vestibulo-ocular reflex. While the program was no longer in the research phase, Dai continued to accept patients. According to Dai, success was measured as a 50% reduction of symptoms.Recent research reveals a very small percentage of MdDS cases may be related to optokinetic nystagmus (OKN). See also
Motion sickness (seasickness, travel sickness)
Space adaptation syndrome (Space flight "zero-g" and return)


== References ==